Sunday, August 16, 2020 7:28:35 AM
@ $1 - the market cap will be $2 B +
CEO clearly says dilution for trials - he will have dilute crazily and then carry reverse split.
NeuroRx is a partner and is conducting trials.
Co market cap - $ 1.13 B
April Price - 3.8 cents Today - 54 cents
- Co does not have an approved product
- co is conducting trial for Covid
- co had cash of $137,000 at the start of the year
- Co does not have a CEO
- co is run by Chairman (Ram Sevalaraju) who is biotech analyst with HC Weightworth
- co needs at least $20 million to run the trials and do not have any money
- if approved they talk about making $100-200 million sales
https://themarket.ch/interview/relief-therapeutics-our-drug-could-generate-hundreds-of-millions-of-dollars-per-year-ld.2478
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM